Author: Mukuntha Subburayan

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...

Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...

Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...

TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...

Enfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial  showed that treatment with...

Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival  (PFS) and overall...